Atrial Fibrillation Market Research Report – Forecast to 2027

Atrial Fibrillation Market Research Report: By Type (Paroxysmal and Others), by Treatment (Medications, Non-Surgical Procedures, and Surgical Procedures), by End-User (Hospitals, Electrophysiology Labs, and Ambulatory Surgical Centers)—Forecast till 2027

ID: MRFR/HC/5058-HCR | August 2022 | Region: Global | 90 Pages         

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Atrial Fibrillation Market, by Type

6.1 Introduction

6.2 Paroxysmal Atrial Fibrillation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Persistent Atrial Fibrillation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Permanent Atrial Fibrillation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Atrial Fibrillation Market, by Treatment

7.1 Introduction

7.2 Medications

7.2.1 Blood Thinners

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2 Rate controllers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3 Rhythm controllers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Non-surgical procedures

7.3.1 Catheter ablation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.2 Electrical cardioversion

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Surgical procedures

7.4.1 Pacemaker implantation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4.2 Open-heart maze procedure

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Atrial Fibrillation Market, by End-User

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Electrophysiology Labs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Ambulatory Surgical Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Atrial Fibrillation Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Johnson & Johnson Services, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Abbott

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Medtronic Plc

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Boston Scientific Corporation

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 MicroPort Scientific Corporation

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Biotronik SE & Co. KG

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Koninklijke Philips N.V.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 AtriCure, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 CardioFocus

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Osypka AG

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Siemens AG

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Biosense Webster, Inc.

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Sichuan Jinjiang Electronic Science and Technology Co., Ltd.

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 CathRx Ltd.

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Vanguard AG

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Atrial Fibrillation Industry

Chapter 13. Appendix

 

LIST OF TABLES

Table 1 Global Atrial Fibrillation Market Synopsis, 2020–2027

Table 2 Global Atrial Fibrillation Market Estimates and Forecast, 2020-2027(USD Million)

Table 3 Global Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 4 Global Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 5 Global Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 6 Global Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 7 North America: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 8 North America: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 9 North America: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 10 North America: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 11 US: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 12 US: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 13 US: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 14 US: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 15 Canada: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 16 Canada: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 17 Canada: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 18 Canada: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 19 South America: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 20 South America: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 21 South America: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 22 South America: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 23 Europe: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 24 Europe: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 25 Europe: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 26 Europe: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 27 Western Europe: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 28 Western Europe: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 29 Western Europe: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 30 Western Europe: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 31 Eastern Europe: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 32 Eastern Europe: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 33 Eastern Europe: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 34 Eastern Europe: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 35 Asia-Pacific: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 36 Asia-Pacific: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 37 Asia-Pacific: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 38 Asia-Pacific: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

Table 39 Middle East & Africa: Atrial Fibrillation Market, by Type, 2020-2027(USD Million)

Table 40 Middle East & Africa: Atrial Fibrillation Market, by Treatment, 2020-2027(USD Million)

Table 41 Middle East & Africa: Atrial Fibrillation Market, by End-User, 2020-2027(USD Million)

Table 42 Middle East & Africa: Atrial Fibrillation Market, by Region, 2020-2027(USD Million)

LIST OF FIGURES


Figure 1 Research Process

Figure 2 Segmentation for Global Atrial Fibrillation Market

Figure 3 Segmentation Market Dynamics for Global Atrial Fibrillation Market

Figure 4 Global Atrial Fibrillation Market Share, by Type, 2020 (%)

Figure 5 Global Atrial Fibrillation Market Share, by Treatment, 2020 (%)

Figure 6 Global Atrial Fibrillation Market Share, by End-User, 2020 (%)

Figure 7 Global Atrial Fibrillation Market Share, by Region, 2020 (%)

Figure 8 North America: Atrial Fibrillation Market Share, by Country, 2020 (%)

Figure 9 Europe: Atrial Fibrillation Market Share, by Country, 2020 (%)

Figure 10 Asia-Pacific: Atrial Fibrillation Market Share, by Country, 2020 (%)

Figure 11 Middle East & Africa: Atrial Fibrillation Market Share, by Country, 2020 (%)

Figure 12 Global Atrial Fibrillation Market: Company Share Analysis, 2020 (%)

Figure 13 Johnson & Johnson Services, Inc.: Key Financials

Figure 14 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 15 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 16 Abbott: Key Financials

Figure 17 Abbott: Segmental Revenue

Figure 18 Abbott: Geographical Revenue

Figure 19 Medtronic Plc: Key Financials

Figure 20 Medtronic Plc: Segmental Revenue

Figure 21 Medtronic Plc: Geographical Revenue

Figure 22 Boston Scientific Corporation: Key Financials

Figure 23 Boston Scientific Corporation: Segmental Revenue

Figure 24 Boston Scientific Corporation: Geographical Revenue

Figure 25 MicroPort Scientific Corporation: Key Financials

Figure 26 MicroPort Scientific Corporation: Segmental Revenue

Figure 27 MicroPort Scientific Corporation: Geographical Revenue

Figure 28 Biotronik SE & Co. KG: Key Financials

Figure 29 Biotronik SE & Co. KG: Segmental Revenue

Figure 30 Biotronik SE & Co. KG: Geographical Revenue

Figure 31 Koninklijke Philips N.V.: Key Financials

Figure 32 Koninklijke Philips N.V.: Segmental Revenue

Figure 33 Koninklijke Philips N.V.: Geographical Revenue

Figure 34 AtriCure, Inc.: Key Financials

Figure 35 AtriCure, Inc.: Segmental Revenue

Figure 36 AtriCure, Inc.: Geographical Revenue

Figure 37 CardioFocus: Key Financials

Figure 38 CardioFocus: Segmental Revenue

Figure 39 CardioFocus: Geographical Revenue

Figure 40 Osypka AG: Key Financials

Figure 41 Osypka AG: Segmental Revenue

Figure 42 Osypka AG: Geographical Revenue

Figure 43 Siemens AG: Key Financials

Figure 44 Siemens AG: Segmental Revenue

Figure 45 Siemens AG: Geographical Revenue

Figure 46 Biosense Webster, Inc.: Key Financials

Figure 47 Biosense Webster, Inc.: Segmental Revenue

Figure 48 Biosense Webster, Inc.: Geographical Revenue

Figure 49 Sichuan Jinjiang Electronic Science and Technology Co., Ltd.: Key Financials

Figure 50 Sichuan Jinjiang Electronic Science and Technology Co., Ltd.: Segmental Revenue

Figure 51 Sichuan Jinjiang Electronic Science and Technology Co., Ltd.: Geographical Revenue

Figure 52 CathRx Ltd.: Key Financials

Figure 53 CathRx Ltd.: Segmental Revenue

Figure 54 CathRx Ltd.: Geographical Revenue

Figure 55 Vanguard AG: Key Financials

Figure 56 Vanguard AG: Segmental Revenue

Figure 57 Vanguard AG: Geographical Revenue

Atrial Fibrillation Market

Atrial Fibrillation Market is expected to register a CAGR of 6.5% with USD 3,470.85 Million by 2030

Segmentation

By Type Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation Permanent Atrial Fibrillation
By Treatment Medications Non Surgical Procedures Surgical Procedures
By End User Hospitals Electrophysiology Labs Ambulatory Surgical Centers

Key Players

  • Johnson & Johnson Services
  • Inc.
  • Abbott
  • Medtronic Plc
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Biotronik SE & Co. KG
  • Koninklijke Philips N.V.
  • AtriCure
  • Inc.
  • CardioFocus
  • Osypka AG

Drivers

  • Growing geriatric population
  • Rise in medical tourism
Speak to Analyst Request a Free Sample

Atrial Fibrillation Market Overview
 
It is estimated that the atrial fibrillation market is expected to reach USD 11123.8 million at a CAGR 11.2 % during the forecast period of 2018–2023. Atrial fibrillation is a condition in which the heart beats erratically rather than normally. The atria, or top chambers of the heart, quiver rapidly, and blood flow slows or stagnates as a result. The ventricles also beat unevenly and do not adequately push blood around the body. The industry is predicted to develop due to factors such as an aging population and an increase in medical tourism. Obesity, hypertension, metabolic syndrome, and diabetes are all contributing to the expansion of the atrial fibrillation industry. The most prevalent type of arrhythmia, atrial fibrillation (AF), causes an irregular and typically rapid heart rhythm. A rise in the global prevalence of atrial fibrillation has been documented. The rising number of persons suffering from atrial fibrillation is a primary driver of this industry. A favorable regulatory environment will also help this business expand.
 
In people over the age of 65, atrial fibrillation (AFib) is the most common chronic arrhythmia. This number is likely to rise as the population continues to age. As a result, rising rates of CVD and atrial fibrillation are likely to boost the market's growth, and the high cost of treatment is putting a strain on the economies of various countries. As a result of the aforementioned factors, the market under consideration is predicted to expand throughout the forecast period.

Key players


Johnson & Johnson Services, Inc., Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG, Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co., Ltd., CathRx Ltd., and Vanguard AG are some of the key players in the global atrial fibrillation market.


Segmentation


The global atrial fibrillation market has been segmented into type, treatment, and end-user.


The market, on the basis of type, has been segmented into paroxysmal atrial fibrillation, persistent atrial fibrillation, and permanent atrial fibrillation.


The market, on the basis of treatment, has been segmented into medications, non-surgical procedures, and surgical procedures.


The market, based on medications, has been segmented blood thinners, rate controllers, and rhythm controllers.


The atrial fibrillation market, based on non-surgical procedures, has been segmented into electrical cardioversion and catheter ablation.


Catheter ablation segment is projected to hold the largest share in the market, as it is a minimally invasive type of surgery which is the most preferred and used, as it lessens the risk of complications, whereas electric cardioversion is estimated to be the fastest growing segment because of its specificity of treatment and decreased recurrence rate.


The market, based on surgical procedures, has been segmented into pacemaker implantation and open-heart maze procedure.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The atrial fibrillation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The atrial fibrillation market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Atrial Fibrillation Market Share (%), by Region, 2017


Atrial Fibrillation Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global atrial fibrillation market owing to a the rise in the adoption of innovative technologies and procedures for the treatment of atrial fibrillation, and advanced healthcare facilities and infrastructure. According to the Centers for Disease Control and Prevention in 2017, an estimated 2.7 to 6.1 million people in the United States have atrial fibrillation (AFib).


Europe is expected to hold the second largest position in the global atrial fibrillation market. The market growth in this region is attributed to the availability of funds for research, and favorable reimbursement scenario. According to a journal published by European Heart Network, approximately 10 million people in Europe live with the atrial fibrillation condition.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population susceptible to cardiac diseases, continuously developing economies and rising prevalence of cardiovascular diseases.


On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to growing government initiatives for the healthcare sector.


Global Atrial Fibrillation Market, by Type



  • Paroxysmal atrial fibrillation

  • Persistent atrial fibrillation

  • Permanent atrial fibrillation


Global Atrial Fibrillation Market, by Treatment



  • Medications

  • Non-surgical procedures





    • Electrical cardioversion

    • Catheter ablation





  • Surgical procedures





    • Pacemaker implantation

    • Open-heart maze procedure




Global Atrial Fibrillation Market, by End-user



  • Hospitals

  • Electrophysiology Labs

  • Ambulatory Surgical Centers


Global Market, by Region



  • Americas


    • North America


      • US

      • Canada

      • South America



  • Europe


    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Middle East & Africa


    • Middle East

    • Africa



Recent Development


Tempus announced in March 2021 that the US FDA had granted their ECG Analysis Platform Breakthrough Device Designation. The technology, which was created in conjunction with Geisinger, helps clinicians identify individuals who are at risk of developing atrial fibrillation (AFib) or atrial flutter.
 
The DiamondTemp Ablation (DTA) system, which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) who have been refractory to medication therapy, was approved by the Food and Drug Administration (FDA) in February 2021. The DiamondTemp system uses diamonds to provide ablations in a temperature-controlled, irrigated radiofrequency (RF) ablation device.

Intended Audience



  • Electrophysiology Centers

  • Medical Device Companies

  • Research and Development (R&D) Companies

  • Government and Medical Research Institutes

  • Academic Institutes and Universities

  • Healthcare Institutions



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 11123.8 million
  CAGR   11.2 % (2018–2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Treatment, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Johnson & Johnson Services, Inc., Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG, Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co., Ltd., CathRx Ltd., and Vanguard AG
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers

  • Growing geriatric population
  • Rise in medical tourism


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    on the basis of treatment, the market of atrial fibrillation has been segmented into medications, non-surgical procedures, and surgical procedures and medications further segmented into blood thinners, rate controllers, and rhythm controllers.

    Increasing prevalence of AF cases among elderly population and increasing technological developments are the major tailwinds pushing the growth of the global Atrial fibrillation market.

    North America holds the largest share in the global atrial fibrillation market, followed by Europe and the Asia Pacific, respectively.

    Carima, Agricore, Biosense Webster, St. Jude Medical, and Medtronic, are some of the major players operating in the global atrial fibrillation market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global atrial fibrillation market adopt to gain a larger competitive advantage.

    Catheter ablation, a sub-segment of surgical products holds the majority shares in the global atrial fibrillation market.